Development of a Supramolecular Hydrogel for Intraperitoneal Injections
© 2023 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH..
Local intraperitoneal drug administration is considered a challenging drug delivery route. The therapeutic efficiency is low, mainly due to rapid clearance of drugs. To increase the intraperitoneal retention time of specific drugs, a pH-sensitive supramolecular hydrogel that can act as a drug delivery vehicle is developed. To establish the optimal formulation of the hydrogel and to study its feasibility, safety, and tissue compatibility, in vitro, postmortem, and in vivo experiments are performed. In vitro tests reveal that a hydrogelator formulation with pH ≥ 9 results in a constant viscosity of 0.1 Pa·s. After administration postmortem, the hydrogel covers the parietal and visceral peritoneum with a thin, soft layer. In the subsequent in vivo experiments, 14 healthy rats are subjected to intraperitoneal injection with the hydrogel. Fourteen and 28 days after implantation, the animals are euthanized. Intraperitoneal exposure to the hydrogel is not resulted in significant weight loss or discomfort. Moreover, no macroscopic adverse effects or signs of organ damage are detected. In several intra-abdominal tissues, vacuolated macrophages are found indicating a physiological degradation of the synthetic hydrogel. This study demonstrates that the supramolecular hydrogel is safe for intraperitoneal application and that the hydrogel shows good tissue compatibility in rats.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Macromolecular bioscience - 24(2024), 1 vom: 20. Jan., Seite e2300005 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wintjens, Anne G W E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal model |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 17.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mabi.202300005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354397052 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354397052 | ||
| 003 | DE-627 | ||
| 005 | 20240117231912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mabi.202300005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM354397052 | ||
| 035 | |a (NLM)36934315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wintjens, Anne G W E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a Supramolecular Hydrogel for Intraperitoneal Injections |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH. | ||
| 520 | |a Local intraperitoneal drug administration is considered a challenging drug delivery route. The therapeutic efficiency is low, mainly due to rapid clearance of drugs. To increase the intraperitoneal retention time of specific drugs, a pH-sensitive supramolecular hydrogel that can act as a drug delivery vehicle is developed. To establish the optimal formulation of the hydrogel and to study its feasibility, safety, and tissue compatibility, in vitro, postmortem, and in vivo experiments are performed. In vitro tests reveal that a hydrogelator formulation with pH ≥ 9 results in a constant viscosity of 0.1 Pa·s. After administration postmortem, the hydrogel covers the parietal and visceral peritoneum with a thin, soft layer. In the subsequent in vivo experiments, 14 healthy rats are subjected to intraperitoneal injection with the hydrogel. Fourteen and 28 days after implantation, the animals are euthanized. Intraperitoneal exposure to the hydrogel is not resulted in significant weight loss or discomfort. Moreover, no macroscopic adverse effects or signs of organ damage are detected. In several intra-abdominal tissues, vacuolated macrophages are found indicating a physiological degradation of the synthetic hydrogel. This study demonstrates that the supramolecular hydrogel is safe for intraperitoneal application and that the hydrogel shows good tissue compatibility in rats | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a animal model | |
| 650 | 4 | |a development | |
| 650 | 4 | |a in vivo safety | |
| 650 | 4 | |a intraperitoneal delivery | |
| 650 | 4 | |a peritoneal cavity | |
| 650 | 4 | |a supramolecular hydrogel | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 700 | 1 | |a Fransen, Peter-Paul K H |e verfasserin |4 aut | |
| 700 | 1 | |a Lenaerts, Kaatje |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a van Almen, Geert C |e verfasserin |4 aut | |
| 700 | 1 | |a van Steensel, Sebastiaan |e verfasserin |4 aut | |
| 700 | 1 | |a Gijbels, Marion J |e verfasserin |4 aut | |
| 700 | 1 | |a de Hingh, Ignace H J T |e verfasserin |4 aut | |
| 700 | 1 | |a Dankers, Patricia Y W |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvy, Nicole D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Macromolecular bioscience |d 2004 |g 24(2024), 1 vom: 20. Jan., Seite e2300005 |w (DE-627)NLM151409706 |x 1616-5195 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:e2300005 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mabi.202300005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 20 |c 01 |h e2300005 | ||